Valence Labs
@valence_ai
Followers
6K
Following
1K
Media
306
Statuses
886
Decoding biology to radically improve lives. Powered by @recursionpharma
Montreal
Joined April 2018
1/ At Valence Labs, @RecursionPharma's AI research engine, we’re focused on advancing drug discovery outcomes through cutting-edge computational methods Today, we're excited to share our vision for building virtual cells, guided by the predict-explain-discover framework 🧵
3
20
94
3/ We only have 8 presentation slots and sign-ups close on November 3rd. Make sure to RSVP below 👇 RSVP here:
0
0
0
2/ We want to connect the people reimagining how drug discovery happens, to share ideas, spark collaborations, and explore ways to build together. If you want to present a “Show & Tell”, we review submissions on a rolling, first-come, first-served basis.
1
0
0
1/ Valence Labs is bringing together next generation of Montréal researchers and innovators in Bio-AI. We are hosting a Bio-AI Show & Tell — a quick and fun showcase of ideas, demos and projects in ML. RSVP here: https://t.co/ldmysp9qiO
1
3
8
Currently Palantir ($PLTR) trades at nearly 20× revenue — but NextNRG Inc ($NXXT) trades at just 3× revenue. Charlie Munger and Warren Buffett made billions spotting these kinds of irrational gaps between price and value. 📊 Facts: THIS COMPANY JSUT MADE ~$70M and market cap
0
4
93
5/ If you’re attending ICML, make sure to connect with @jasonhartford and Ihab to learn more about the research happening at Valence Labs and @Recursion.
0
0
1
4/ “Towards Scientific Discovery with Dictionary Learning: Extracting Biological Concepts from Microscopy Foundation Models” Link:
1
0
0
3/ “A Cross Modal Knowledge Distillation & Data Augmentation Recipe for Improving Transcriptomics Representations through Morphological Features” Link:
1
0
0
2/ ”ViTally Consistent: Scaling Biological Representation Learning for Cell Microscopy” Link:
openreview.net
Large-scale cell microscopy screens are used in drug discovery and molecular biology research to study the effects of millions of chemical and genetic perturbations on cells. To use these images in...
1
0
0
1/ Valence Labs, @Recursion's AI research engine, is at ICML this week! Two of our scientists, @jasonhartford and Ihab Bendidi are presenting posters on work featured in their papers 👇🧵
1
0
15
3/ By combining SynFlowNet with Boltz-2, this new release aims to accelerate the design of high-affinity binders for more efficient early-stage drug discovery. Check out the GitHub repository here: https://t.co/13b1iV1OKP Learn more about Boltz-2: https://t.co/qPBSMwcJb5
0
0
9
2/ Originally introduced by Valence Labs, Recursion’s AI research engine, SynFlowNet helps ensure generative models propose molecules that are not only novel but also synthetically feasible.
1
0
2
1/ We are excited to open-source the SynFlowNet-Boltz-2 trainer today! 🧵
1
21
124
Pleased to have hosted the 2025 Molecular Machine Learning Conference last week at @Mila_Quebec Thank you to everyone who joined us and shared their valuable insights! We hope to see you all again soon.
We had a great turnout for the 2025 Molecular Machine Learning Conference (#MoML) at @Mila_Quebec. Sponsored by Recursion and @valence_ai along with Genesis Therapeutics and Braidwell, the annual event convenes researchers from academia and industry to discuss how ML methods can
0
1
9
Looking forward to seeing everyone this Wednesday, June 18th, at @Mila_Quebec in Montréal. We anticipate a day of engaging discussions, talks and poster presentations, exploring research at the intersection of machine learning and drug discovery. Agenda: https://t.co/bR8iSdCn0J
0
0
4
Proud to share @RecursionPharma's exciting announcement on Boltz-2! Valence Labs, Recursion’s AI research engine, contributed to the foundational research supporting the @MIT team led by Regina Barzilay Learn more about Boltz-2 here:
rxrx.ai
RxRx3 is a publicly available map of biology that represents a small subset – less than 1% – of Recursion’s total dataset.
Learn more about Boltz-2, the new open source AI model from MIT and Recursion capable of predicting protein binding affinity with unprecedented speed, scale and accuracy. ▪️ Boltz-2 is the first model to combine structure and binding affinity prediction, approaching the accuracy
2
4
42
3/ MoML is an excellent opportunity to engage with leading minds, explore cutting-edge research, and connect with the community in TechBio. We encourage everyone to secure their spot before it’s too late! Register now to be part of MoML 2025:
0
0
0
2/ Our list of speakers include: — Aaron Newman (@Stanford) — Smita Krishnaswamy (@Yale) — Gabriele Corso (@MIT) — Kirill Neklyudov (@Mila_Quebec) — Emmanuel Noutahi (@valence_ai | @Recursion) — Michael LeVine (@genesistxai)
1
0
0
1/ We're excited to announce our speaker lineup for MoML 2025! Join us on June 18th, 2025, at Mila in Montreal for a day focused on the intersection of machine learning and drug discovery. 🧵
1
2
14
What’s needed for a virtual cell to succeed in drug discovery? A new perspective paper from Recursion and our AI research engine @valence_ai lays out our vision for a virtual cell as a system that can reliably drive the discovery of new drugs via an iterative loop of: predict,
1
12
36
6/ Learn more Try the app: https://t.co/aW1DaHdKMf Read the blog: https://t.co/jVSZ6fdTXW Read the paper: https://t.co/QewQrbmLUy Access the code:
github.com
A repository for reproducing experiments from the TxPert paper - valence-labs/TxPert
0
1
2